skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Broken chain

New guidance from the from the UK Medicines and Healthcare products Regulatory Agency (MHRA) says that Great Britain will continue to use and recognize the CE-marking on devices and in vitro diagnostics until 30 June 2023. After that, companies accessing the home device and diagnostics markets will need to affix a new “UKCA” mark on devices.

The guidance, issued on 1 September, brings clarity regarding future use of the CE marking after the end of the UK’s transition out of the EU on 31 December.

The UK medtech industry had anticipated the continued recognition of the CE marking for a limited period by the UK, and guidance on this was issued initially, but later withdrawn.

There has been no suggestion that UK notified bodies’ CE-markings would be recognized in the EU 27, as mutual recognition is not provided for. Indeed, the UKCA mark will not be recognized by the EU, EEA or in Northern Ireland, the UK Association of British HealthTech Industries (ABHI) said in a new factsheet. Products currently requiring a CE marking will still need it for sale in these markets. The UK-EU Brexit talks resume on 7 September.

UKCA Does Not Apply In Northern Ireland

Moreover, the UKCA requirement will not apply to Northern Ireland traders, where slightly different arrangements will apply to accommodate the terms of the Northern Ireland Protocol, the ABHI says.

The new route to market will be available and will run in parallel to the CE marking for the rest of the UK from 1 January 2021, but the UKCA must be used from 1 July 2023.   

Devices To Be Registered With The MHRA In 2021

All devices placed on the UK market must be registered with the MHRA under the following schedule in 2021, with grace periods of four, eight and 12 months, depending on the class of device under the existing EU medical device directives:    

  • By 30 April 2021 for class III, class IIb implantables and active implantable devices under the Medical Devices Directive (MDD); and IVDs under List A IVDs of the In Vitro Diagnostics Directive (IVDD);

  • By 31 August 2021 for all other class IIb, class IIa devices and List B IVDs and self-test IVDs; and

  • By 31 December 2021 for all class I devices and general IVDs.

Manufacturers of class I products that do not require UK Conformity Assessment Body (CAB) involvement can self-declare from January 2021. All manufacturers will need to affix a new UKCA number to devices.  There is no information to date on the form of UKCA (UK Conformity Assessed) mark.

The post-Brexit legislation that will apply in Great Britain are the MDD, IVDR and the Active Implantables Medical Devices Directive (AIMDD), which are given effect through the UK Medical Devices Regulations 2002. In the form in which they exist on 1 January 2021, they will continue to have effect in Great Britain after the transition period. The UK is in the process of drafting standalone primary devices legislation in the Medicines and Medical Devices (MMD) bill.

UK notified bodies with designations under the MDD, IVDD or AIMDD will have their designations rolled over automatically, without having to undergo a new designation process. As of 1 January, they will be known as "Approved Bodies." From 1 January, UK enforcement or market surveillance powers available in respect of the UKCA mark will apply to CE-marked devices. Devices placed on the market will need to have one or other of these marks.

The forthcoming EU MDR and IVDR will not be be UK retained law, under the EU Withdrawal Agreement Act, and as such will not automatically apply in Great Britain. They will apply in Northern Ireland, from 26 May 2021, and 26 May 2022, respectively, in line with the EU’s implementation deadlines.

The MHRA guidance further reminds manufacturers:

  • Conformity assessments carried out by UK notified bodies/Approved Bodies will not be recognized by the EU after 31 December – even if the assessment was carried out before the end of the UK's transition period;

  • UK medical devices entering the EU market after 31 December must undergo mandatory third-party conformity assessment, via an EEA-based notified body;

  • Great Britain-based ARs will not be recognized in the EU from 1 January, regardless of when products were placed on the market;

  • Great Britain-based manufacturers supplying CE-marked devices to the EU market will need to establish an AR based in the EU or Northern Ireland to register and act on their behalf; and

  • UK manufacturers will need to ensure that devices meet EU labeling requirements in order to be placed on the EU market.

Special Rules For Northern Ireland

Manufacturers wishing to place a device on the Northern Ireland market must register with the MHRA. Manufacturers established in Great Britain must designate a Northern Ireland or EU Authorized Representative (AR) in order to place a device on the Northern Ireland market. Where the designated AR is based in Northern Ireland, it will be required to register devices of all classes placed on the Northern Ireland market (including custom-made devices and IVDs) with the MHRA. Where the AR is based in the EU, there is no requirement to register class I and custom-made devices or general IVDs. All other devices placed on the Northern Ireland market must be registered with MHRA.

For Northern Ireland market access, the MHRA guidance states that: "UK Approved Bodies will be able to conduct conformity assessments for the purposes of the Northern Ireland market. Where a device has been assessed by a UK Approved Body, the UK(NI) mark will accompany, but not replace, the CE mark. Products carrying both the CE mark and UK(NI) mark cannot be placed on the EU market." It adds: "UKCA marked devices will not be accepted on the Northern Ireland market unless accompanied by the CE or CE UK(NI) mark."

MHRA's Ongoing UK Role

The MHRA will continue to be responsible for the designation and monitoring of UK CABs. Manufacturers outside the UK and wanting to access the UK market must establish and register both a UK place of business and a UK Responsible Person (UKRP), by the end of the grace periods as above. The UKRP will assume the responsibilities of the manufacturer in terms of registering the device with the MHRA.

Manufacturers based outside the EEA who have an AR established in Northern Ireland will not need to designate a UKRP when placing a device on the Northern Ireland market. In such cases, the Northern Ireland-based AR will be able to register devices with the MHRA on the manufacturer’s behalf, the MHRA guidance adds.

ABHI chief executive Peter Ellingworth said the guidance is a practical and pragmatic response to the end of the transition period. The ABHI has advocated alignment with EU regulatory arrangements in the short to medium term. “A two-and-a-half-years period of continuity is much preferable to the emergency provisions that would have otherwise needed to be put in place," he said.

Devices that have been CE marked by Northern Ireland traders will continue to be accepted on the Great Britain market beyond 30 June 2023. This will apply to devices that have been self-certified or have undergone mandatory third-party conformity assessment by an EEA-based notified body.

MDSAP and IMDRF Also On The Agenda?

Along with the draft standalone UK MMD legislation, the UKCA mark is a further step in the creation of a self-regulating medtech sector once the UK is outside the influence of EU rules and regulations. Further stages could see the UK adopt the Medical Device Singe Audit Program (MDSAP) and become an independent member of the International Medical Device Regulators Forum (IMDRF). (Also see "UK Medtech Gets A Role In Post-Brexit Trade Deal Negotiations" - Medtech Insight, 28 Aug, 2020.) 

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: